Mechanisms of inhibition of herpes simplex virus type 2 growth by 28-mer phosphorothioate oligodeoxycytidine.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Journal of Biological Chemistry

• Publication date

  1990-11-25

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 2173699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides

  1990cited by this paper
• Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?

  1989cited by this paper
• Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide.

  1989cited by this paper
• Initial interaction of herpes simplex virus with cells is binding to heparan sulfate

  1989cited by this paper
• Characterization of oligonucleotide transport into living cells.

  1989cited by this paper
• Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase.

  1989cited by this paper
• Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

  1989cited by this paper
• Oligodeoxynucleotides as inhibitors of gene expression: a review.

  1988cited by this paper
• Physicochemical properties of phosphorothioate oligodeoxynucleotides.

  1988cited by this paper
• Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

  1987cited by this paper
• Induction of virus enzymes by phorbol esters and n-butyrate in Epstein-Barr virus genome-carrying Raji cells.

  1987cited by this paper
• Identification and preliminary mapping with monoclonal antibodies of a herpes simplex virus 2 glycoprotein lacking a known type 1 counterpart.

  1984cited by this paper
• Number of receptor sites from Scatchard and Klotz graphs: a constructive critique.

  1983cited by this paper
• Anti-herpes simplex virus and anti-human cell growth activity of E-5-propenyl-2'-deoxyuridine and the concept of selective protection in antivirus chemotherapy

  1980cited by this paper
• Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells.

  1980cited by this paper
• Properties of herpes simplex virus type 1 and type 2 DNA polymerase.

  1980cited by this paper
• Differences in attachment between herpes simplex type 1 and type 2 viruses to neurons and glial cells

  1980cited by this paper
• Evidence for herpes simplex virus type-selective receptors on cellular plasma membranes.

  1979cited by this paper
• The deoxyribonuclease induced after infection of KB cells by herpes simplex virus type 1 or type 2. I. Purification and characterization of the enzyme.

  1978cited by this paper
• Transcription of structural and intervening sequences in the ovalbumin gene and identification of potential ovalbumin mRNA precursors.

  1978cited by this paper
• Deoxythymidine kinase induced in HeLa TK- cells by herpes simplex virus type I and type II. II. Purification and characterization.

  1976cited by this paper
• Comparison of the virion proteins specified by herpes simplex virus types 1 and 2

  1975cited by this paper
• Detection of specific sequences among DNA fragments separated by gel electrophoresis.

  1975cited by this paper
• Isolation of a Herpes Simplex Virus-Specific Antigenic Fraction Which Stimulates the Production of Neutralizing Antibody

  1972cited by this paper
• Proteins Specified by Herpes Simplex Virus V. Purification and Structural Proteins of the Herpesvirion

  1972cited by this paper
• Viropexis of herpes simplex virus by HeLa cells.

  1969cited by this paper
• A graphic method for the determination and presentation of binding parameters in a complex system.

  1967cited by this paper

• Antiviral application of Carbohydrate Polymers: A review.

  2023cites this paper
• Rise and fall of fomivirsen, the first approved gene silencing medicine : A historical review

  2022cites this paper
• History of Research on Antisense Oligonucleotide Analogs

  2021cites this paper
• From DEPARTMENT OF MEDICINE, HUDDINGE Karolinska Institutet, Stockholm, Sweden STRATEGIES FOR MODULATION OF DENDRITIC CELL RESPONSES

  2012cites this paper
• Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27.

  2009cites this paper
• A Proviral Role for CpG in Cytomegalovirus Infection1

  2009cites this paper
• This information is current as Infection A Proviral Role for CpG in Cytomegalovirus

  2009cites this paper
• Amphipathic DNA Polymers Exhibit Antiherpetic Activity In Vitro and In Vivo

  2008cites this paper
• Amphipathic DNA Polymers Exhibit Anti-herpetic Activity 1 In vitro and In vivo 2 3 Running Title: Herpetic activity of amphipathic DNA polymers 4 5

  2008cites this paper
• Antisense Inhibition of Virus Infections

  2008cites this paper
• Amphipathic DNA Polymers are Candidate Vaginal Microbicides and Block Herpes Simplex Virus Binding, Entry and Viral Gene Expression

  2007cites this paper
• Antiviral therapy targeting viral polymerase.

  2006cites this paper
• Binding and transfer of an oligodeoxynucleotide containing the translation initiation site of the BCL2 mRNA into K562 cells

  2005cites this paper
• An oligonucleotide decoy for nuclear factor-kappa B inhibits tumor necrosis factor-alpha-induced human umbilical cord vein endothelial cell tissue factor expression in vitro.

  2004cites this paper
• An oligonucleotide decoy for nuclear factor-κB inhibits tumor necrosis factor-α-induced human umbilical cord vein endothelial cell tissue factor expression in vitro

  2004cites this paper
• NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS

  2004cites this paper
• Optimization of Functional Efficacy of Phosphorothioate‐Modified Oligonucleotides in a Human CD8+ T‐Cell Ex Vivo Expansion Model

  2003cites this paper
• Cationic lipids enhanced cellular uptake and activity of bcl-2 antisense oligodeoxynucleotide G3139 in HL-60 cells.

  2001cites this paper
• Antisense oligonucleotides in cutaneous therapy.

  2001cites this paper
• Suppression of tumor necrosis factor secretion from white blood cells by synthetic antisense phosphorothioate oligodeoxynucleotides.

  2000cites this paper
• Reactive derivatives of oligonucleotide phosphorothioate analogues: IV. Site-directed modification of nucleic acids and intramolecular alkylation of phosphorothioate groups

  2000cites this paper
• Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression.

  1999cites this paper
• 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection.

  1999cites this paper
• Clinical Antiviral Activities

  1998cites this paper
• In Vitro Cellular Uptake, Distribution, and Metabolism of Oligonucleotides

  1998cites this paper
• Antisense Research and Application

  1998cites this paper
• In vitro expression and antisense inhibition of HIV-1 regulatory proteins Tat, Rev and Nef

  1998cites this paper
• Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset.

  1998cites this paper
• Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015.

  1997cites this paper
• Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides.

  1997cites this paper
• Inhibition of Human Cytomegalovirus DNA Replication with a Phosphorothioate Cholesteryl-Modified Oligonucleotide is Mediated by Rapid Cellular Association and Virus-Facilitated Nuclear Localization

  1997cites this paper
• Studies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation

  1997cites this paper
• Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines.

  1996cites this paper
• Pulmonary delivery of antiviral drugs in liposome aerosols

  1996cites this paper
• Herpes Simplex Virus-Mediated Activation of Human Immunodeficiency Virus Is Inhibited by Oligonucleoside Methylphosphonates That Target Immediate-Early mRNAs 1 and 3

  1996cites this paper
• Internalization of oligodeoxynucleotide antisense to type-1 plasminogen activator inhibitor mRNA in endothelial cells: a three-dimensional reconstruction by confocal microscopy.

  1996cites this paper
• Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA

  1996cites this paper
• Inhibition of growth of estrogen receptor positive and estrogen receptor negative breast cancer cells in culture by AA-etherA, a stable 2-5A derivative.

  1996cites this paper
• Liposomal targeting of bcl-2 antisense oligonucleotides with enhanced stability into human myeloma cell lines.

  1996cites this paper
• Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus

  1996cites this paper
• Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice.

  1996cites this paper
• Progress in antisense oligonucleotide therapeutics.

  1996cites this paper
• Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene.

  1996cites this paper
• Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37

  1995cites this paper
• Suppression of Human Immunodeficiency Virus Type 1 Activity in Vitro by Oligonucleotides Which Form Intramolecular Tetrads (*)

  1995cites this paper
• cytomegalovirus genes UL 36 and UL 37 . intron-exon boundary of human oligonucleotide complementary to the Potent antiviral activity of an antisense

  1995cites this paper
• Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.

  1995cites this paper
• The therapeutic potential of antisense oligonucleotides.

  1995cites this paper
• In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.

  1995cites this paper
• Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides (*)

  1995cites this paper
• Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.

  1995cites this paper
• Inhibition of HIV-1 Replication and Activation of RNase L by Phosphorothioate/Phosphodiester 2′,5′-Oligoadenylate Derivatives (*)

  1995cites this paper
• Inhibition of herpes simplex virus in culture by oligonucleotides composed entirely of deoxyguanosine and thymidine.

  1995cites this paper
• Expression of human cytomegalovirus UL36 and UL37 genes is required for viral DNA replication

  1995cites this paper
• Directed Mutagenesis of Deoxyguanosine Site at Arginine 79 Up-regulates Turnover on Deoxyadenosine Kinase Subunit of Heterodimeric Enzyme from Lactobacillus acidophilus R26 (*)

  1995cites this paper
• Inhibition of human immunodeficiency virus type-1 env expression by C-5 propyne oligonucleotides specific for Rev-response element stem-loop V.

  1994cites this paper
• Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells.

  1994cites this paper
• Inhibition of Friend murine leukemia virus activity by guanosine/thymidine oligonucleotides.

  1994cites this paper
• Use of Partially Phosphorothioated "Antisense" Oligodeoxynucleotides for Sequence-Dependent Modulation of Hematopoiesis in Culture

  1994cites this paper
• Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus.

  1994cites this paper
• Inhibition of human immunodeficiency virus type 1 activity in vitro by oligonucleotides composed entirely of guanosine and thymidine.

  1994cites this paper
• Effects of Sequence of Thioated Oligonucleotides on Cultured Human Mammary Epithelial Cells

  1993cites this paper
• Use of Cationic Lipids to Enhance the Biological Activity of Antisense Oligonucleotides

  1993cites this paper
• A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-κ-B Causes Sequence-Specific Immune Stimulation

  1993cites this paper
• Current concepts in antisense drug design.

  1993cites this paper
• Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region

  1993cites this paper
• Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

  1993cites this paper
• Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification

  1993cites this paper
• Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells.

  1993cites this paper
• Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5.

  1993cites this paper
• Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.

  1992cites this paper
• Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.

  1992cites this paper
• Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.

  1992cites this paper
• Antisense oligonucleotides for therapeutic intervention.

  1991cites this paper
• Pharmaceutical applications

  1991cites this paper
• Antisense technology.

  1991cites this paper
• In vitro toxicology and pharmacokinetics of antisense oligonucleotides.

  1991cites this paper
• Oligonucleotides as therapeutic agents.

  1991cites this paper
• Cellular uptake of antisense oligodeoxynucleotides

  1991cites this paper